Sign In
Buy RIGL
Rigel Pharmaceuticals Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $0.93 |
| EPS actual | $1.46 |
| EPS Surprise | 56.99% |
| Revenue estimate | 66.574M |
| Revenue actual | 69.462M |
| Revenue Surprise | 4.34% |
| Release date | Aug 05, 2025 |
| EPS estimate | $1.97 |
| EPS actual | $3.28 |
| EPS Surprise | 66.50% |
| Revenue estimate | 62.307M |
| Revenue actual | 101.685M |
| Revenue Surprise | 63.20% |
| Release date | May 06, 2025 |
| EPS estimate | $0.140 |
| EPS actual | $0.630 |
| EPS Surprise | 350.00% |
| Revenue estimate | 48.318M |
| Revenue actual | 53.333M |
| Revenue Surprise | 10.38% |
| Release date | Mar 04, 2025 |
| EPS estimate | $0.300 |
| EPS actual | $0.80 |
| EPS Surprise | 166.67% |
| Revenue estimate | 57.59M |
| Revenue actual | 57.596M |
| Revenue Surprise | 0.0104% |
Last 4 Quarters for Rigel Pharmaceuticals
Below you can see how RIGL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 04, 2025 |
| Price on release | $22.08 |
| EPS estimate | $0.300 |
| EPS actual | $0.80 |
| EPS surprise | 166.67% |
| Date | Price |
|---|---|
| Feb 26, 2025 | $22.33 |
| Feb 27, 2025 | $21.78 |
| Feb 28, 2025 | $23.06 |
| Mar 03, 2025 | $22.37 |
| Mar 04, 2025 | $22.08 |
| Mar 05, 2025 | $20.29 |
| Mar 06, 2025 | $19.70 |
| Mar 07, 2025 | $20.52 |
| Mar 10, 2025 | $19.53 |
| 4 days before | -1.12% |
| 4 days after | -11.55% |
| On release day | -8.11% |
| Change in period | -12.54% |
| Release date | May 06, 2025 |
| Price on release | $18.26 |
| EPS estimate | $0.140 |
| EPS actual | $0.630 |
| EPS surprise | 350.00% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $19.56 |
| May 01, 2025 | $18.72 |
| May 02, 2025 | $19.36 |
| May 05, 2025 | $19.11 |
| May 06, 2025 | $18.26 |
| May 07, 2025 | $18.47 |
| May 08, 2025 | $18.90 |
| May 09, 2025 | $18.77 |
| May 12, 2025 | $18.61 |
| 4 days before | -6.65% |
| 4 days after | 1.92% |
| On release day | 1.15% |
| Change in period | -4.86% |
| Release date | Aug 05, 2025 |
| Price on release | $24.24 |
| EPS estimate | $1.97 |
| EPS actual | $3.28 |
| EPS surprise | 66.50% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $21.01 |
| Jul 31, 2025 | $21.06 |
| Aug 01, 2025 | $21.91 |
| Aug 04, 2025 | $22.67 |
| Aug 05, 2025 | $24.24 |
| Aug 06, 2025 | $29.81 |
| Aug 07, 2025 | $30.44 |
| Aug 08, 2025 | $31.70 |
| Aug 11, 2025 | $33.46 |
| 4 days before | 15.37% |
| 4 days after | 38.04% |
| On release day | 22.98% |
| Change in period | 59.26% |
| Release date | Nov 04, 2025 |
| Price on release | $28.38 |
| EPS estimate | $0.93 |
| EPS actual | $1.46 |
| EPS surprise | 56.99% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $29.40 |
| Oct 30, 2025 | $31.62 |
| Oct 31, 2025 | $31.58 |
| Nov 03, 2025 | $30.65 |
| Nov 04, 2025 | $28.38 |
| Nov 05, 2025 | $37.85 |
| Nov 06, 2025 | $36.12 |
| Nov 07, 2025 | $35.19 |
| Nov 10, 2025 | $34.55 |
| 4 days before | -3.47% |
| 4 days after | 21.74% |
| On release day | 33.37% |
| Change in period | 17.52% |
Rigel Pharmaceuticals Earnings Call Transcript Summary of Q3 2025
Rigel reported an excellent Q3 2025 driven by strong commercial execution and pipeline progress. Total revenue was $69.5M with record net product sales of $64.1M (up 65% YoY). Year-to-date net product sales of $166.6M have already surpassed full-year 2024, prompting Rigel to raise 2025 revenue guidance to $285M–$290M (net product sales $225M–$230M), and the company expects positive net income for 2025. Commercial growth was broad-based: TAVALISSE ($44.7M, +70% YoY), GAVRETO ($11.1M, +56% YoY) and REZLIDHIA ($8.3M, +50% YoY). Cash and equivalents rose to $137.1M. On the clinical side, the company completed dose-escalation enrollment for R289 (oral dual IRAK1/4 inhibitor) in relapsed/refractory lower-risk MDS, will present updated dose-escalation data (Oct 28 cutoff) in an oral ASH presentation (Dec 7), and has opened dose-expansion (randomizing up to 40 transfusion-dependent patients to 500 mg once vs twice daily). Olutasidenib development is expanding via multiple collaborations (MD Anderson, CONNECT TarGeT-D glioma arm, MyeloMATCH), with several studies enrolling. Rigel continues to seek in‑licenses/acquisitions to complement its hematology/oncology portfolio while maintaining financial discipline.
